ReviewCell biochemistry and biophysics2026
Ferroptosis-Inflammation Crosstalk: Mechanistic Insights and Emerging Drug Targets.
Review in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis, a non-apoptotic form of regulated cell death characterized by iron accumulation and lipid peroxidation, has recently established its crucial role in inflammation and immune - related diseases. The current review aims at offering a comprehensive synthesis of the Interaction between ferroptosis and inflammation that governs the ferroptosis-inflammation axis, in which the inflammation environment and cell death process operates that can influence each other through difficult molecular pathways. In this context, this article discusses how inflammatory signalling pathways works, in terms of the inflammation environment, as exemplified by the pathway of the IFN-γ JAK/STAT1 axis, that regulates the ferroptotic pathway by inhibiting system Xc
Indexed as
Identifiers
42584759What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.